News

As providers were challenged to care for patients with severe COVID-19 In the first year of the pandemic, antibiotic usage increased. Listen to clinicians talk about this specific challenge and how prescribing practices evolved over time.

Routine infant, child, and adolescent vaccination rates and coverage were lower in 2020 than in 2019, particularly for Black children.

Today, the Advisory Committee on Immunization Practices (ACIP) unanimously voted the CDC should approve Pfizer-BioNTech and Moderna booster doses for all adults.

The report assesses progress of a US national action plan to combat antimicrobial resistance, called for by 2015 World Health Assembly.

From its origins as a serendipitous discovery to being successfully prescribed for nearly a century, antibiotics remain a foundation of medicine. However it has major ongoing challenges including the rise of superbugs and the development of antimicrobial resistance (AMR). There are some prospective strategies to combat AMR on the horizon.

The FDA has authorized the Moderna and Pfizer-BioNTech COVID-19 booster shots for all Americans 18 and older.

Providers and key stakeholders weigh in on this significant topic.

The European Center for Diseases Prevention and Control published data today showing the greatest decrease in antibiotic consumption in 2 decades coincided with the COVID-19 pandemic.

AstraZeneca’s PROVENT and TACKLE stage 3 trials show its vaccine AZD7442 significantly reduced the risk of severe or fatal COVID-19, even among high-risk populations.

The National Academies report reviews several challenges, and ways to overcome them for optimal antimicrobial stewardship.

Retesting positive COVID-19 PCR tests from asymptomatic, nonexposed persons and tests stored next to a specimen with high viral load identified false positives.

The National Academy of Medicine released 4 reports with COVID-19-influenced recommendations to prepare and respond to an influenza pandemic.

CEO Christopher Burns spoke about their investigational therapy pipeline, the long view perspective for the company, and how the federal government’s use of the nomenclature innovation might actually hinder incremental improvements in antibiotic development.

A new report suggests FDA and CDC deliberations may result in booster doses of the mRNA vaccine becoming available by this weekend.

Investigators analyzed data from COVID-NET across 14 states as this variant quickly become the dominant strain within the United States.

Previous research suggested vaccine efficacy significantly dips after 6 months, but a new study finds COVID-19 cellular immunity remains strong.

States with policy that permitted adolescents to independently choose to receive HPV vaccination had a significantly higher immunization uptake.

This agreement with the Medicines Patient Pool (MPP) would allow licensing of the company’s antiviral treatment candidate, PF-07321332, internationally to numerous countries.

Betsy Wonderly-Trainor discusses CARB-X's mission to fund novel antibiotics, preventatives, and diagnostics in the fight against antimicrobial resistance.

Just 39 cases among more than 2.2 million doses administered.

A recent study supported the use of a therapeutic dose of heparin for moderately ill patients with COVID-19, with results showing a significant reduction in all-cause death despite no significant reduction in a composite of death, mechanical ventilation and ICU admission.

Bias against injection drug users can inhibit them from receiving potentially lifesaving care, such as HIV pre-exposure prophylaxis (PrEP). Community-based responses like syringe service programs help combat this stigma.

India is the world’s leading consumer of antibiotics, and Amita Gupta, MD, is researching how the country can best mitigate the spread of antimicrobial resistance.

Antimicrobial stewardship efforts need infectious disease doctors, but they are in short supply. Telehealth may be the answer.

Clinical care is evolving in this area and shows promise in the various modalities and therapies that are going through clinical trials.

2 doses of the India-developed vaccine BBV152 offer 77.8% protection against symptomatic COVID-19 disease.

During the C Diff Foundation's Annual conference, providers and stakeholders offered insights on the latest investigational therapies and modalities as they advance through clinical trials.

Dr. Nicola Petrosillo discusses treating C difficile infection and maintaining antimicrobial stewardship during the height of the COVID-19 pandemic in Italy.